1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Asset Management - Cryptocurrency
Lite Strategy, Inc.

Lite Strategy, Inc.

LITS
Lite Strategy, Inc.US flagNASDAQ Capital Market
1.03
USD
+0.04
- -
35.05MMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
- -
- -
- -
- -
12.63
0.78
1.38
6.09
6.18
6.54
7.33
9.8
- -
- -
Basic EPS, GAAP
-22.02
-27.06
-23.18
-12.13
1.45
-19.34
-4.73
-10.36
-7.34
-8.75
-4.78
2.67
-2.39
-1.78
Free Cash Flow per Basic Share
-19.84
-19.44
-19.91
-10.38
1.87
-10.15
-8.33
7.33
-5.81
-7.91
-7.88
-7.58
-3.13
-0.3
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
1.75
- -
- -
Book Value per Share
-189.55
-123.07
-110.72
-102.91
-94.71
-103.5
-65
-61.13
-56.82
-60.12
-60.93
-58.26
-60.66
-13.52
Tangible Book Value per Share
67.72
44.62
42.11
24
27.44
24.22
13.4
16.92
8.79
8.42
3.7
4.96
2.54
1.66
Basic Weighted Avg Shares
1
1
1
2
2
2
4
5
6
6
7
7
7
34
Sales/Revenue/Turnover
- -
- -
- -
- -
23
2
5
28
35
41
49
65
- -
- -
Operating Margin (%)
- -
- -
- -
- -
10.25
-1,762.39
-940.9
-92.58
-173.65
-185.48
-75.31
38.96
- -
- -
Depreciation Expense
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Net Income, GAAP
-11
-27
-33
-21
3
-40
-17
-47
-41
-54
-32
18
-16
-61
Effective Tax Rate (%)
- -
- -
- -
- -
0.04
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
- -
- -
11.48
-2,470.28
-342.2
-169.96
-118.73
-133.8
-65.22
27.23
- -
- -
Working Capital
34
45
59
41
50
96
68
195
145
143
87
32
17
10
LT Debt
- -
- -
- -
- -
- -
- -
- -
- -
7
9
11
- -
- -
- -
Total Equity
35
45
60
42
51
50
48
77
49
52
25
33
17
57
Return on Invested Capital (%)
- -
- -
- -
- -
5.15
- -
- -
- -
- -
- -
- -
72.3
- -
- -
Return on Capital (%)
- -
- -
- -
- -
-1.52
- -
- -
- -
- -
- -
- -
-4.55
- -
- -
Return on Common Equity (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -

Capital Structure

FRC

•

in mil. unless spec.
Sep'26
Dec'26
Mar'26
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
36
37
35
Market Capitalization
35
32
40

Working Capital

FRC

•

in mil. unless spec.
Sep'26
Dec'26
Mar'26
Total Current Assets
13
11
11
Cash, Cash Equivalents & STI
10
9
10
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
1
1
1
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-5.08%
-19.5%
-48.73%
Free Cash Flow
-124.28%
-40.63%
-58.71%
Net Income, GAAP
-199.49%
-73.53%
-189.69%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
65
- -
- -
- -
65
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
8.46
-1.66
-1.37
- -
2.67
2025
-1.2
-0.4
-0.39
- -
-2.39
2026
-0.12
-0.82
-0.66
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
1.75
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

APIChatGPT
CEO
Justin J. File
Full Time Employees
4
Sector
Healthcare
Industry
Asset Management - Cryptocurrency
Address
9920 Pacific Heights Blvd. San Diego CA United States of America 92121
IPO Date
Dec 18, 2003
CIK
0001262104
Website
litestrategy.com
Similar Companies
Bitwise Funds Trust (IMST)
Osprey Bitcoin Trust (OBTC)
Franklin Ethereum ETF (EZET)
GraniteShares YieldBOOST Ether ETF (XEY)
Grayscale Avalanche Staking ETF (GAVA)
CleanSpark, Inc. (CLSK)
Business
Lite Strategy, Inc. (NASDAQ: LITS) is a clinical-stage pharmaceutical company that develops novel therapies for cancer treatment alongside digital asset treasury management focused on Litecoin (LTC) accumulation; its pharmaceutical portfolio includes voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor, zandelisib, an oral once-daily selective PI3K inhibitor, and ME-344, an intravenous small molecule inhibitor of mitochondrial oxidative phosphorylation targeting human epidermal growth factor receptor 2 negative breast cancer, colorectal cancer, and solid tumors. The company engages in active treasury management to increase LTC holdings per share as its primary metric of shareholder value, positioning itself as the largest public equity vehicle for Litecoin exposure through compliant institutional-grade strategies. Lite Strategy, Inc. was incorporated in 2000, is headquartered in San Diego, California, and operates primarily in the United States within the healthcare and biotechnology sectors targeting oncology patients and institutional investors seeking digital asset access. In recent developments, the company rebranded from MEI Pharma, Inc. to Lite Strategy, Inc. in September 2025, adopting the LITS ticker and launching a new website to reflect its strategic pivot toward Litecoin treasury operations. It raised $100 million through a PIPE financing in July 2025, acquired 929,548 LTC tokens as its primary reserve asset, and formed a strategic partnership with GSR for liquidity, risk management, and treasury advisory services. Additional key changes include the announcement of a $25 million share repurchase program in October 2025 to optimize capital returns when shares trade below market net asset value, the sale of its clinical asset ME-344 to Aardvark Therapeutics, and maintenance of $12.21 million in working capital with no outstanding debt as reported in first quarter fiscal 2026 results.

Company News

APIChatGPT

  • globenewswire.com

    Lite Strategy to Attend Panel at Litecoin Foundation Summit in Amsterdam

  • globenewswire.com

    Lite Strategy Leads Strategic Investment in LitVM

  • globenewswire.com

    Lite Strategy Reports Fiscal 2026 Third Quarter Results

  • globenewswire.com

    Lite Strategy Reports Fiscal 2026 Second Quarter Results

  • newsfilecorp.com

    LiTHOS Announces Board and Management Change

  • defenseworld.net

    Lite Strategy (NASDAQ:LITS) Director James Flynn Buys 70,000 Shares